

1296876

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*March 16, 2005*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 60/527,630**

**FILING DATE: *December 05, 2003***

**RELATED PCT APPLICATION NUMBER: *PCT/US04/40444***



Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office



14230 U.S. PTO

PTO/SB/16 (08-03)


Approved for use through 07/31/2006. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV 335774888 US

03917 U.S. PTO  
60/527630

| INVENTOR(S)   |  |  |              |   |              |
|---|--|--|--------------|---|--------------|
| Given Name (first and middle [if any])  |  | Family Name or Surname                         |              | Residence<br>(City and either State or Foreign Country)   |              |
| Joseph D. Nicolas   |  | Buxbaum Ramoz                                  |              | New York, New York<br>New York, New York  |              |
| Additional inventors are being named on the <u>0</u> separately numbered sheets attached hereto   |  |  |              |   |              |
| TITLE OF THE INVENTION (500 characters max)   |  |  |              |   |              |
| METHODS AND COMPOSITIONS FOR AUTISM RISK ASSESSMENT   |  |  |              |   |              |
| Direct all correspondence to: CORRESPONDENCE ADDRESS  |  |  |              |   |              |
| <input type="checkbox"/> Customer Number: <div style="border: 1px solid black; width: 280px; height: 30px; display: inline-block;"></div>                       |  |  |              |   |              |
| OR  |  |  |              |   |              |
| <input checked="" type="checkbox"/> Firm or Individual Name   |  | Elie H. Gendloff, Ph.D., Esq.                  |              |   |              |
| Address   |  | Amster, Rothstein & Ebenstein                  |              |   |              |
| Address   |  | 90 Park Avenue                                 |              |   |              |
| City  |  | New York                                       |              | State   | NY           |
| Country   |  | USA  |              | Zip   | 10016        |
|   |  | Telephone                                      | 212-336-8000 | Fax   | 212-336-8001 |
| ENCLOSED APPLICATION PARTS (check all that apply)   |  |  |              |   |              |
| <input checked="" type="checkbox"/> Specification Number of Pages <u>35</u>   |  | <input type="checkbox"/> CD(s), Number _____   |              |   |              |
| <input checked="" type="checkbox"/> Drawing(s) Number of Sheets <u>2</u>  |  | <input type="checkbox"/> Other (specify) _____ |              |   |              |
| <input type="checkbox"/> Application Date Sheet. See 37 CFR 1.76  |  |  |              |   |              |
| METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT  |  |  |              |   |              |
| <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.  |  |  |              | FILING FEE<br>Amount (\$)   |              |
| <input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees.  |  |  |              | <div style="border: 1px solid black; width: 120px; height: 50px; text-align: center; vertical-align: middle;">\$80.00</div> |              |
| <input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <u>01-1785</u> |  |  |              |   |              |
| <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.   |  |  |              |   |              |
| The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.                         |  |  |              |   |              |
| <input checked="" type="checkbox"/> No.   |  |  |              |   |              |
| <input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____  |  |  |              |   |              |

[Page 1 of 2]

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME Elie H. Gendloff, Ph.D., Esq.TELEPHONE 212-336-8000Date December 5, 2003REGISTRATION NO. 44,704

(if appropriate)

Docket Number: 7703/3**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**AMSTER  
ROTHSTEIN  
& EBENSTEIN LLP**

*Intellectual Property Law*

90 Park Avenue  
New York NY 10016

Main 212 336 8000

Fax 212 336 8001

Web [www.arelaw.com](http://www.arelaw.com)

**Partners**

Morton Amster  
Jesse Rothstein (1934 - 2003)  
Daniel Ebenstein  
Philip Gouffried  
Michael J. Berger  
Neil M. Zipkin  
Anthony F. Lo Cicero  
Kenneth P. George  
Abraham Kasdan, Ph.D.  
Ira E. Silfin  
Chester Rothstein  
Craig J. Arnold

**Senior Counsel**

Charles R. Macedo  
Mark J. Rosenberg  
Kenneth M. Bernstein

**Of Counsel**

Jerry D. Dainow

**Associates**

Neal L. Rosenberg  
Nancy M. Dodderidge  
Patrick Boland\*  
Trebzor Lloyd  
Joseph M. Casino

John S. Economou  
Michael V. Solomita  
Holly Pekowsky  
Michael P. Kenney  
Marion P. Metelski\*  
Max Vern  
Dana R. Metes  
Karl J. Kolbinger  
Brian A. Comack  
Richard S. Mandaro  
Marc J. Jason  
Elie H. Gendloff, Ph.D.  
David Mitnick

Charles W. Rath  
David A. Boag  
Karen J. Bernstein  
Mathieu Hausig  
Jung S. Hahn  
Reiko Kaji  
Alan D. Miller, Ph.D.  
Hsin-Hsin (Ginger)

\*Not admitted in New York

December 5, 2003

Via Express Mail

Elie H. Gendloff, Ph.D., Esq.

Direct 212 336 8108

e-mail [egendloff@arelaw.com](mailto:egendloff@arelaw.com)

Mail Stop Provisional Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

"Express Mail" mailing label No. EV 335774888 US  
Date of Deposit: December 5, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name: Elie H. Gendloff, Ph.D., Esq.

Signature: 

Re: Provisional Application for Patent (Small Entity Status Claimed)  
TITLE: METHODS AND COMPOSITIONS FOR AUTISM RISK ASSESSMENT  
Inventors: Joseph D. Buxbaum and Nicolas Ramoz  
Our File: 7703/3

Dear Sir:

Pursuant to 37 C.F.R. §1.53, enclosed please find a new Provisional Application for Patent in the names of Joseph D. Buxbaum and Nicolas Ramoz entitled METHODS AND COMPOSITIONS FOR AUTISM RISK ASSESSMENT, including the following:

1. Provisional Application for Patent Cover Sheet (Form PTO/SB/16) (1 page);
2. a provisional application comprising (37 pages), including a specification (31 pages), claims (3 pages), abstract (1 page) and drawings (2 sheets);
3. an AR&E check for \$80.00 to cover the filing fee; and
4. a return receipt postcard.


December 5, 2003

Please acknowledge receipt of the enclosed papers by stamping the enclosed postcard and returning the same.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicants  
90 Park Avenue  
New York, New York 10016  
(212) 697-5995

Dated: December 5, 2003  
New York, New York

By:   
Elie H. Gendloff, Ph.D., Esq.  
Registration No. 44,704

EHG/kmm

## METHODS AND COMPOSITIONS FOR AUTISM RISK ASSESSMENT

### Background

#### (1) Field of the Invention

- 5           The present invention generally relates to autism risk assessment. More specifically, methods and compositions are provided that are useful for estimating risk for having autism.

#### (2) Description of the Related Art

#### References cited

- 10    1.     Lord C, Leventhal BL, Cook EH Jr: Quantifying the phenotype in autism spectrum disorders. *Am J Med Genet* 2001; 105:36-38
2.     Lord C, Cook EH, Leventhal BL, Amaral DG: Autism spectrum disorders. *Neuron* 2000; 28:355-63
3.     Rapin I, Katzman R: Neurobiology of autism. *Ann Neurol* 1998; 43:7-14
- 15    4.     Folstein SE, Rosen-Sheidley B: Genetics of autism: complex aetiology for a heterogeneous disorder. *Nat Rev Genet* 2001; 2:943-955
5.     Rutter M: Concepts of autism: a review of research. *J Child Psychol Psychiatry* 1968; 9:1-25
6.     Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, Rutter
- 20    M: Autism as a strongly genetic disorder: evidence from a British twin study. *Psychol Med* 1995; 25:63-77
7.     Lucinio J and Alvarado J: Progress in the genetics of autism. *Mol Psychiatry* 2002; 7:1012-1017
8.     Philippe A, Guilloud-Bataille M, Martinez M, Gillberg C, Rastam M,
- 25    Sponheim E, Coleman M, Zappella M, Aschauer H, Penet C, Feingold J, Brice A,

- Leboyer M: Analysis of ten candidate genes in autism by association and linkage. *Am J Med Genet* 2002; 114:125-128
9. Buxbaum JD, Silverman JM, Smith CJ, Greenberg DA, Kilifarski M, Reichert J, Cook EH Jr, Fang F, Song C-Y, Vitale R: Association between a GABRB3 polymorphisms and autism. *Mol Psych* 2002; 7:311-316
10. Jamain S, Betancur C, Quach H, Philippe A, Fellous M, Giros B, Gillberg C, Leboyer M, Bourgeron T: Linkage and association of the glutamate receptor 6 gene with autism. *Mol Psychiatry* 2002; 7:302-310
11. Kim SJ, Cox N, Courchesne R, Lord C, Corsello C, Akshoomoff N, Guter S, Leventhal BL, Courchesne E, Cook EH Jr: Transmission disequilibrium mapping at the serotonin transporter gene (SLC6A4) region in autistic disorder. *Mol Psychiatry* 2002; 7:278-288
12. Veenstra-Vanderweele J, Cook E Jr, Lombroso PJ: Genetics of childhood disorders: XLVI. Autism, part 5: genetics of autism. *J Am Acad Child Adolesc Psychiatry* 2003; 42:116-118
13. Buxbaum JD, Silverman JM, Smith CJ, Kilifarski M, Reichert J, Hollander E, Lawlor BA, Fitzgerald M, Greenberg DA, Davis KL: Evidence for a susceptibility gene for autism on chromosome 2 and for genetic heterogeneity. *Am J Hum Genet* 2001; 68:1514-1520
14. International Molecular Genetic Study of Autism Consortium (IMGSAC): A genomewide screen for autism: strong evidence for linkage to chromosomes 2q, 7q, and 16p. *Am J Hum Genet* 2001; 69:570-581
15. Shao Y, Raiford KL, Wolpert CM, Cope HA, Ravan SA, Ashley-Koch AA, Abramson RK, Wright HH, DeLong RG, Gilbert JR, Cuccaro ML, Pericak-Vance MA: Phenotypic homogeneity provides increased support for linkage on chromosome 2 in autistic disorder. *Am J Hum Genet* 2002; 70:1058-1061
16. Bacchelli E, Blasi F, Biondolillo M, Lamb JA, Bonora E, Barnby G, Parr J, Beyer KS, Klauck SM, Poustka A, Bailey AJ, Monaco AP, Maestrini E: Screening of

- nine candidate genes for autism on chromosome 2q reveals rare nonsynonymous variants in the cAMP-GEFII gene; *Mol Psychiatry* 2003; 8:916-24
17. Weiss LA, Escayg A, Kearney JA, Trudeau M, MacDonald BT, Mori M, Reichert J, The AGRE Consortium, Buxbaum JD, Meisler MH: Sodium channels SCN1A, SCN2A and SCN3A in familial autism. *Mol Psychiatry* 2002; 8:182-190
18. Geschwind DH, Sowinski J, Lord C, Iversen P, Shestack J, Jones P, Ducat L, Spence SJ: The autism genetic resource exchange: a resource for the study of autism and related neuropsychiatric conditions. *Am J Hum Genet* 2001; 69:463-466
19. Lord C, Rutter M, Le Couteur A: Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. *J Autism Dev Disord.* 1994; 24:659-685
20. Olivier M, Chuang LM, Chang MS, Chen YT, Pei D, Ranade K, de Witte A, Allen J, Tran N, Curb D, Pratt R, Neefs H, de Arruda Indig M, Law S, Neri B, Wang L, Cox DR: High-throughput genotyping of single nucleotide polymorphisms using new biplex invader technology. *Nucleic Acids Res* 2002; 30:e53
21. Spielman RS, Ewens WJ: A sibship test for linkage in the presence of association: the sib transmission/disequilibrium test. *Am J Hum Genet* 1998; 62:450-458
22. Durner M, Vieland VJ, Greenberg DA: Further evidence for the increased power of LOD scores compared with nonparametric methods. *Am J Hum Genet* 1999; 64:281-289
23. Hodge SE, Vieland VJ, Greenberg DA: HLODs remain powerful tools for detection of linkage in the presence of genetic heterogeneity. *Am J Hum Genet* 2002; 70:556-559
24. Xie X, Ott J: Testing linkage disequilibrium between a disease gene and marker loci. *Am J Hum Genet* 1993; 53:(Suppl)110

25. del Arco A, Satrustegui J: Molecular cloning of Aralar, a new member of the mitochondrial carrier superfamily that binds calcium and is present in human muscle and brain. *J Biol Chem* 1998; 273:23327-23334
26. Palmieri L, Pardo B, Lasorsa FM, del Arco A, Kobayashi K, Iijima M,  
5 Runswick MJ, Walker JE, Saheki T, Satrustegui J, Palmieri F: Citrin and aralar1 are Ca(2+)-stimulated aspartate/glutamate transporters in mitochondria. *EMBO J* 2001; 20:5060-5069
27. Ramos M, del Arco A, Pardo B, Martinez-Serrano A, Martinez-Morales JR, Kobayashi K, Yasuda T, Bogonez E, Bovolenta P, Saheki T, Satrustegui J:  
10 Developmental changes in the Ca<sup>2+</sup>-regulated mitochondrial aspartate-glutamate carrier aralar1 in brain and prominent expression in the spinal cord. *Dev Br Research* 2003; 143:33-46
28. Filipek PA, Juranek J, Smith M, Mays LZ, Ramos ER, Bocian M, Masser-Frye D, Laulhere TM, Modahl C, Spence MA, Gargus JJ: Mitochondrial dysfunction in  
15 autistic patients with 15q inverted duplication. *Ann Neurol* 2003; 53:801-804
29. Badner JA, Gershon ED: Regional meta-analysis of published data supports linkage of autism with markers on chromosome 7. *Mol Psychiatry* 2002; 7:56-66
30. Botstein D, Risch N: Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. *Nat*  
20 *Genet* 2003; 33:(Suppl)228-237
31. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard J-P, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel J-F, Sahbatou M, Thomas G: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's  
25 disease. *Nature* 2001; 411:599-603
32. Horikawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, Hara M, Hinokio Y, Lindner TH, Mashima H, Schwarz PE, del Bosque-Plata L, Horikawa Y, Oda Y, Yoshiuchi I, Colilla S, Polonsky KS, Wei S, Concannon P, Iwasaki N, Schulze J,



- Baier LJ, Bogardus C, Groop L, Boerwinkle E, Hanis CL, Bell GI: Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. *Nat Genet* 2000; 26:163-75
33. Yan H, Yuan W, Velculescu VE, Vogelstein B, Kinzler KW: Allelic variation in  
5 human gene expression. *Science* 2002; 297:1143-5
34. Bray NJ, Buckland PR, Owen MJ, O'Donovan MC: Cis-acting variation in the expression of a high proportion of genes in human brain. *Hum Genet* 2003; 149-53
35. Lasorsa FM, Pinton P, Palmieri L, Fiermonte G, Rizzuto R, Palmieri F: Recombinant expression of the Ca(2+)-sensitive aspartate/glutamate carrier  
10 increases mitochondrial ATP production in agonist-stimulated Chinese hamster ovary cells. *J Biol Chem* 2003; 278:38686-92
36. Nyholt DR. All LODs are not created equal. *Am J Hum Genet* 200;282-288.

Autism or autistic disorder (MIM #209850) is a neurodevelopmental disorder characterized by a deficit in verbal and non-verbal communication,  
15 impairments in reciprocal social interactions, and patterns of repetitive or stereotyped behaviors and interests (1-3). The sex-ratio is 4:1 male to female, and the prevalence of the disease is currently thought to possibly be above 1 per 1000 persons (4). Autism appears to be the most highly genetic of the psychiatric disorders as evidenced by the high risk of autism in additional children in families  
20 with an autistic child (estimated to be 50 to 100 times greater than that expected by chance) and the concordance rate for monozygotic twins being much higher than that of dizygotic twins (5). Heritability estimates of idiopathic autism are above 90% (6), so much of the disorder can be attributed to a genetic etiology. However, autism does not follow a simple Mendelian mode of transmission (i.e.,  
25 dominant or recessive transmission) but is clearly a polygenic disease (4). A commonly accepted genetic model involves several genes (between 5 to 10) that interact to produce the disorder.

A genetic mutation or variant segregating with autism has yet to be unequivocally identified. Candidate genes for studies of autism range from genes that are thought to play a role in neurodevelopmental pathways, comorbidity or behavior, such as genes in the serotonergic pathway or reelin (4, 7, 8). A few  
5 polymorphisms in several genes have been associated with the disorder in certain studies, but not in others (4, 9-11).

Several independent studies involving genome-wide scans have now been published and point to significant linkage between autism and chromosome 2q and 7q regions (4, 12). Our studies defined chromosome 2q24-q33 as a susceptibility  
10 region for autism with a peak at D2S335, particularly evident in families with more severe autism [as defined by delayed onset (over 36 months) of phrase speech (phrase speech delay, PSD) (MIM #606053)] (NPL score of 3.32 and a HLOD of 2.99) (13). Using a cohort of 152 autism sibling-pair families mostly from European countries, the International Molecular Genetic Study of Autism  
15 Consortium (IMGSAC) reported their highest multipoint LOD score (MLS=3.74) at D2S2188 in families with autism with language delay (defined in that study as no single word before 24 months and/or no phrase speech before 33 months) (14). When stricter diagnostic criteria were used, the MLS increased to a value of 4.8. Finally, a study from the Collaborative Autism Team using the PSD criteria to  
20 weight its data also showed a linkage between autism and chromosome region 2q33, with an MLS of 2.86 and a HLOD of 2.12 at D2S116 (15).

D2S335, D2S2188 and D2S116 are localized on chromosome 2 at 171 megabases (Mb), 174.4 Mb and 200.5 Mb, respectively (Figure 1A). This indicates that a critical region of susceptibility for autism occurs near D2S335 and D2S2188  
25 in 2q31. In this interval, several known genes and expressed sequence tags have been mapped (Figure 1B). Recently, the IMGSAC has reported the analysis of nine candidate genes (TBR1, GAD1, DLX1, DLX2, cAMP-GEFII, CHN1, CREB2, HOXD1 and NEUROD1) localized across a 30 Mb region of 2q, that are expressed in the

central nervous system and encode proteins that play a role in neuronal cells or in neurobiological pathways (16). Variants were observed in TBR1, cAMP-GEFII, CHN1, HOXD1 and NEUROD1. However, no evidence was found that any of the candidate genes contributes to autism. In this region, our laboratory, together with  
5 the laboratory of Dr. Miriam Meisler, has previously investigated the neuronal voltage-gated sodium channels type I, II and III (SCN1A, SCN2A and SCN3A) in 117 multiplex autism families (17). Rare mutations were identified, each in single families, that were not observed in controls. These mutations, while of great interest, are not likely to account for the evidence of linkage observed in this  
10 region.

There is thus a need to pinpoint genetic variations associated with autism, in order to be able to determine whether individuals are at particular risk for autism, and to determine the risk for autism in offspring of two individuals. Identification of genetic risk factors would also provide tools and information for elucidating the  
15 causes of autism. The present invention addresses that need.

#### Summary of the Invention

Accordingly, the inventors have discovered that the risk of autism is increased in individuals having the G allele at either or both polymorphism sites rs2056202 and rs2292813 of the SLC25A12 gene.

20 Thus, in some embodiments, the invention is directed to method of evaluating an individual for relative genetic risk for autism. The methods comprise determining the individual's genotype at polymorphism sites rs2056202 and/or rs2292813 of the SLC25A12 gene. In these embodiments, the presence of a G at either of the two sites indicates an increased risk for autism, and the presence of an  
25 increasing number of G's at the sites indicates an increasing risk for autism.

The invention is also directed to sets of two primers suitable for use in polymerase chain reaction, useful for the methods identified immediately above.

The invention is additionally directed to kits comprising the above-identified primers.

In other embodiments, the invention is directed to polynucleotides consisting of any of the sequences of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3,  
5 and SEQ ID NO:4.

The invention is further directed to methods of identifying a form of a genetic polymorphism that is linked to autism. The methods comprise identifying a polymorphism in the SLC25A12 gene and determining whether one form of the polymorphism is present in autistic individuals more than another form. In these  
10 embodiments, in the form that is present more often in autism is linked to autism. The polymorphisms identified by these methods can also be used to determine the risk of an individual to autism.

In further embodiments, the invention is directed to eukaryotic cells comprising a transgenic human SLC25A12 gene, and non-human animals  
15 comprising those cells.

Additionally, the invention is directed to methods of evaluating whether a compound affects autism. The methods comprise contacting the compound with the above described eukaryotic cell, then determining whether the compound affects expression or activity of a product of the SLC25A12 gene. In these  
20 embodiments, a compound that affects expression or activity of the product of the SLC25A12 gene affects autism.

#### Brief Description of the Drawings

FIG. 1 is three graphics showing the genomic organization of the autism susceptibility locus on chromosome region 2q24-q33. Panel A shows the genetic and cytogenetic mapping. Panel B shows the organization of positional candidate  
25 genes. Arrowhead indicates orientation of transcription. Panel C shows the genomic structure of SLC25A12 gene. Variants identified in the present study are indicated

(see text), with the two SNPS focused on in the current study, rs2056202 (I3-21A/G) and rs2292813 (I16+70A/G) underlined.

FIG. 2 is a table showing the results of a relative risk assessment using polymorphisms of the SLC25A12 gene.

## 5 Detailed Description of the Invention

The present invention is based on the discovery of an association between certain polymorphisms in the SLC25A12 gene and autism. This discovery enables various compositions and methods for use in various aspects of autism diagnostics, therapeutics, and research.

10 Thus, in some embodiments, the invention is directed to method of evaluating an individual for relative genetic risk for autism. The methods comprise determining the individual's genotype at polymorphism sites rs2056202 and/or rs2292813 of the SLC25A12 gene. In these embodiments, the presence of a G at either of the two sites indicates an increased risk for autism, and the presence of an  
15 increasing number of G's at the sites indicates an increasing risk for autism.

Any human can be tested using these embodiments, and these methods can also be used to determine the potential risk of the offspring of two individuals for autism, based on the identified genotype of the parents at the relevant polymorphism.

20 The invention is not narrowly limited to any particular method for determining the individual's genotype at the relevant polymorphic sites; the skilled artisan could chose and apply an appropriate method for any particular application without undue experimentation. In some preferred embodiments, the genotype is determined by single strand conformation polymorphism, denaturing high-  
25 performance liquid chromatography, DNA Invader, and/or polymerase chain reaction amplification followed by sequencing. See, e.g., the Example.

In those embodiments employing polymerase chain reaction (PCR), preferred primers for amplifying the appropriate regions are comprise SEQ ID NO:5 and SEQ ID NO:6 (for amplifying the relevant region of rs2056202 [these primers amplify SEQ ID NO:1 or SEQ ID NO:2, depending on the polymorphic form  
5 present]) or SEQ ID NO:7 and SEQ ID NO:8 (for amplifying the relevant region of rs2292813 [amplifying SEQ ID NO:3 or SEQ ID NO:4]).

The invention is also directed to sets of two primers suitable for use in polymerase chain reaction, useful for the methods of determining an individual's risk for autism, as described above. Preferred primer sets are SEQ ID NO:5 and  
10 SEQ ID NO:6, for amplifying the relevant region of rs2056202, and SEQ ID NO:7 and SEQ ID NO:8, for amplifying the relevant region of rs2292813. However, any other primers that are specific for either of the relevant regions of the SLC25A12 gene could also be used, and can be designed without undue experimentation.

In additional embodiments, the invention is directed to kits comprising at  
15 least one set of primers suitable for use in polymerase chain reaction (PCR). The set of primers in these kits amplifies polymorphism site rs2056202 or rs2292813, or both of the SLC25A12 gene. Consistent with the above discussion describing the relevant primers, preferred primer sets are SEQ ID NO:5 and SEQ ID NO:6, for amplifying the relevant region of rs2056202, and SEQ ID NO:7 and SEQ ID NO:8,  
20 for amplifying the relevant region of rs2292813. However, any other primers that are specific for either of the relevant regions of the SLC25A12 gene could also be used. These kits can also comprise instructions for using the set(s) of primers to evaluate an individual for relative genetic risk for autism by determining the genotype of the polymorphic sites re2056202 and/or re2292813 of the SLC25A12  
25 gene. The kits can also comprise other ingredients such as buffers, enzymes and the like, for performing PCR and/or analysis of the PCR product(s).

The invention is additionally directed to PCR products amplified using any of the above-described primer sets. Nonlimiting examples of these PCR products include SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4.

5 The invention is further directed to methods of identifying a form of a genetic polymorphism that is linked to autism. The methods comprise identifying a polymorphism in the SLC25A12 gene and determining whether one form of the polymorphism is present in autistic individuals more than another form. In these embodiments, the form that is present more often in autism is linked to autism. The polymorphisms identified by these methods can also be used to determine the  
10 risk of an individual to autism. Nonlimiting examples of procedures to conduct these methods are provided in the Example. Genetic polymorphisms identified by the above procedure that are associated with autism can also be used to evaluate an individual for relative genetic risk for autism.

15 Since this invention includes the discovery that the SLC25A12 gene is associated with autism, the skilled artisan would understand that cells and multicellular organisms comprising the human SLC25A12 gene are useful for autism research.

Thus, the instant invention is also directed to eukaryotic cells comprising a transgenic human SLC25A12 gene. In some embodiments, these eukaryotic cells  
20 are particularly useful when the transgenic SLC25A12 gene comprises the sequence of SEQ ID NO:2 and/or SEQ ID NO:4, since those sequences are within SLC25A12 genes associated with autism.

In these embodiments, the cell is a yeast cell, or a mammalian cell, such as a brain cell. The cell can also be within a living mammal, such as a transgenic  
25 mammal transfected with the gene.

Thus, in related embodiments, the invention is directed to non-human animals comprising the above described eukaryotic cells. Preferably, the non-human animal of these embodiments is a mammal.

Since it is likely that the SLC25A12 gene product is altered in autism, a mitochondrial aspartate/glutamate carrier (AGC1)(see Example), chemical compounds that affect AGC1 would be expected to affect autism.

Thus, the invention is also directed to methods of evaluating whether a compound affects autism. The methods comprise contacting the compound with any of the above eukaryotic cells and determining whether the compound affects expression or activity of a product of the SLC25A12 gene. In these embodiments, a compound that affects expression or activity of the product of the SLC25A12 gene affects autism. The compounds useful for these embodiments can be a small organic or inorganic molecule or a macromolecule such as an antibody, an aptamer, an siRNA, an antisense compound, etc.

Preferred embodiments of the invention are described in the following examples. Other embodiments within the scope of the claims herein will be apparent to one skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered exemplary only, with the scope and spirit of the invention being indicated by the claims which follow the examples.

#### Example 1.

##### Example summary

**Objective:** Autism/autistic disorder (MIM #209850) is a complex, largely genetic psychiatric disorder. We recently mapped a susceptibility locus for autism to chromosome region 2q24-q33 (MIM #606053). In the present study, we analyzed genes across the 2q24-q33 interval to identify an autism susceptibility gene in this region.

**Method:** Mutation screening of positional candidate genes was performed in two stages. The first stage involved identifying genetic variants in exons and



flanking sequence within candidate genes, in unrelated subjects showing linkage to 2q24-q33, and comparing the frequency of the variants between subjects and controls. Two single nucleotide polymorphisms (SNPs) that showed evidence for divergent distribution between subjects and controls were identified, both within  
5 SLC25A12, a gene encoding the mitochondrial aspartate/glutamate carrier (AGC1). In the second stage, the two SNPs in SLC25A12 were further genotyped in 411 autistic families, and linkage and association tests were carried out in the 197 informative families.

Results: Linkage and association were observed between autistic disorder  
10 and the two SNPs, rs2056202 and rs2292813, found in SLC25A12. Using a single affected per family, evidence for excess transmission was found by the transmission disequilibrium test (TDT) for rs2056202 ( $\chi^2=10.83$ ,  $df=1$ ,  $P=0.001$ ), rs2292813 ( $\chi^2=6.23$ ,  $df=1$ ,  $P=0.01$ ), and a two-locus G\*G haplotype ( $\chi^2=22.10$ ,  $df=1$ ,  $P=0.000003$ ). Using multiple affected individuals per family demonstrated  
15 evidence for linkage by the TDT for rs2056202 ( $\chi^2=8.89$ ,  $df=1$ ,  $P=0.003$ ) and rs2292813 ( $\chi^2=7.28$ ,  $df=1$ ,  $P=0.007$ ), and for the two-locus haplotype ( $\chi^2=20.41$ ,  $df=1$ ,  $P=0.000006$ ). Evidence for linkage was supported by linkage analysis with the two SNPs, with a maximal multipoint NPL score of 1.64 and a maximal multipoint heterogeneity LOD score of 2.28.

20 Conclusions: Our studies demonstrated strong association of SNPs within the SLC25A12 gene with autism.

### Introduction

The aim of the present study was to identify an autism susceptibility gene in the 2q31 region. A systematic screen for genetic variants in affected individuals  
25 identified linkage and association between autism and single nucleotide polymorphisms in the SLC25A12 gene.

### Methods

Subjects. A total of four hundred eleven families were either recruited by the Seaver Autism Research Center (SARC) at Mount Sinai (n=40), co-recruited by SARC and the Autism Genetic Research Exchange (AGRE) (18) (n=127), or recruited by AGRE (n=244). All parents signed an informed consent and potentially affected individuals were assessed by the Autism Diagnostic Interview-Revised (ADI-R) (19). Individuals meeting ADI-R criteria for autism (19) or borderline autism (13) were defined as affected. The cohort (18) and research diagnosis definitions used in the current study (13) have been described. The entire cohort of 411 families included blood samples from more than 2000 individuals, including 720 affected individuals (671 with autism and 49 with borderline autism), and available parents and sibs. The 411 families included 274 multiplex (typically affected sibling-pairs) and 137 trio families. DNA from blood samples or transformed cells were either isolated as detailed in Buxbaum et al., 2001, or provided by the AGRE repository.

Mutation screening. To investigate the involvement of positional candidate genes in autism, we performed a two-stage screen.

In the first stage, exonic and flanking DNA from 35-47 patients from 38 autistic families linked to the chromosome 2q24-q33 region were screened for genetic variants by single strand conformation polymorphism (SSCP) and denaturing high-performance liquid chromatography (DHPLC). The rationale for this approach was to find variants in linked, affected individuals, rather than rely on variants in public databases identified in unaffected individuals. Furthermore, the focus was on exonic sequence and intronic sequence adjacent to exons, as being most likely to harbor functionally important variants.

Primers to amplify exons and flanking regions of positional candidate genes were designed using primer3 software ([http://www-genome.wi.mit.edu/cgi-bin/primer/primer3\\_www.cgi](http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi)) and are available on request. The forward and reverse primers were chosen to produce amplicons of less than 500 bp. Larger

exons, in particular the last exons of the genes, were divided over several amplicons, each with a size of less than 500 base pairs. Primers within flanking introns were situated 26 to 186 bp from the exons. A total of 82 exons of 9 genes were analyzed, using 93 amplicons with an average size of ca. 310 nucleotides.

5        For SSCP, forward primers were labeled using 100  $\mu$ Ci [ $\gamma$ P32]-ATP and 10 units of T4 polynucleotide kinase, according to the protocol provided by Invitrogen. Amplification was carried out using Ampli-Taq Gold Polymerase (Applied Biosystems) in a final volume of 10  $\mu$ l, consisting of 10 ng of genomic DNA, 10 mM Tris-HCl, 50 mM KCl, 2.5mM MgCl, 100  $\mu$ M dNTPs, 10  $\mu$ M radioactively-labeled  
10 forward and unlabeled reverse primers, and 0.5 units of Taq Polymerase. Two  $\mu$ l of radioactively-labeled PCR product was then mixed with 2  $\mu$ l of formamide blue loading buffer, denatured and separated on a non-denaturing MDE 0.5X gel (according to the protocol of BioWhittaker). SSCP were detected by autoradiography.

15        For DHPLC, 8  $\mu$ l of PCR product was screened on the WAVE Nucleic Acid-Fragment Analysis System (according to the manufacturer's protocols). Chromatographic parameters, appropriate analysis temperatures, and melting domains visualization were determined by WAVEMAKER software. Samples were using at least two mobile-phase temperatures to maximize the chances to identify  
20 polymorphisms.

Any amplicons in which variants were detected by either SSCP or DHPLC were then sequenced by direct fluorescent sequencing of purified PCR products using the BIG DYE dideoxy-terminator kit v3.1 (Applied Biosystems) and an ABI3100 DNA sequencer with Performance Optimized Polymer 6 (Applied  
25 Biosystems). Variants were then genotyped in 38 unrelated cases and in 100 controls. Allele frequencies were compared to identify variants with potentially altered frequencies (defined as  $P=0.1$ ) between ethnically matched cases and controls (to reduce the chances for false-positives due to stratification).

In the second stage, variants with frequencies that were potentially altered between cases and controls were then analyzed in the entire cohort of more than 2000 individuals from 411 autistic families. Genotyping was carried out using the biplex DNA Invader method (Third Wave Technologies). The Invader assay is based  
5 on the hybridization of an oligonucleotide probe that completely matches a DNA target and the subsequent cleavage of the overlapping structure by Cleavase VIII, resulting in a target-specific product that is recognized by a fluorescence resonance energy transfer (FRET) cassette (20). Specific oligonucleotide probes corresponding to wild type and mutated SNPs are associated with specific  
10 fluorophores, enabling simultaneous detection of both DNA sequences in a single well. For our studies, diluted aliquots of the PCR products were combined with Invader mix solution (Third Wave Technologies), and incubated for the cleavage reaction in a thermal cycler (PTC-100, MJ Research). The reaction product was then analyzed on a fluorescence plate reader (CytoFluor Series 4000, PerSeptive  
15 Biosystems) using the appropriate parameters of excitation and emission for each fluorophore.

Statistical analysis. Two-tailed chi-square tests ( $\chi^2$ ) were used for comparisons of allelic frequencies and distributions of genotypes between control and autism groups. Fischer's exact test was performed when the number in a group  
20 was less than five. Hardy-Weinberg distribution was examined for each identified polymorphism in autistic and control groups.

Statistical analyses for transmission disequilibrium tests (TDT) were computed with TDT-GENEHUNTER (GENEHUNTER version 2.1, compiled to run on the Unix environment of Mac OS X) and the S-TDT (21) program  
25 (<http://genomics.med.upenn.edu/spielman/TDT.htm>). Two-locus TDT was carried out with TDT-GENEHUNTER using the TDT2 option and the haplotypes were constructed by GENEHUNTER and verified manually to ensure structure.

Haplotypes were determined on the basis of transmission patterns in families in which both parents were genotyped.

For linkage analysis, we used GENEHUNTER PLUS (compiled to run on the Unix environment of Mac OS X). Scores for heterogeneity LOD (HLOD) and nonparametric linkage (NPL) were calculated for both single and multi-point analyses. For HLOD, data were analyzed under both a dominant and recessive model, using 50% penetrance and a value of 0.001 for the disease allele frequency. Such an approach detects linkage under many different conditions irrespective of the “true” underlying inheritance pattern (22, 23).

Linkage disequilibrium (LD) was estimated using a D' value calculated with the 2LD program (24).

### Results

Genes across the 2q31 region were screened for association in two stages as detailed in the Methods. The genes analyzed included glutamate decarboxylase 1 (GAD1) (in collaboration with Drs. Shigeo Kure, Kiyoshi Kanno and Yoichi Matsubara), four hypothetical proteins (FLJ13096, FLJ13984, LOC130672, and FLJ23462, recently identified as duodenal cytochrome b) (in collaboration with Drs. Paolo Gasparini and Massimo Carella), histone acetylase-1 (HAT-1) (in collaboration with Dr. Salah Uddin Qureshi), the cytoplasmic dynein subunit DNCI2, the aspartate/glutamate carrier SLC25A12, and the homeobox protein DLX2 (Figure 1C). These candidate genes were chosen based on their position relative to the positive linkage results from three studies (13-15), their expression in brain tissue, and, in some cases, their known function, their novelty, or the existence of related genes within the region of chromosome 7 showing linkage to autism. For this latter criterion, we note that the linked region of chromosome 7 contains genes paralogous to DNCI2, SLC25A12, DLX1 and DLX2 (i.e., DNCI1, SLC25A13, DLX5 and DLX6).

In the first stage, all known exons (with flanking intronic sequence) of these genes were screened by SSCP and DHPLC for variants in 35 to 47 unrelated individuals chosen from families showing linkage to D2S335 as described in Methods. In the nine genes, 82 exons were screened and 29 SNPs were identified.

5 Frequencies of each variant were then evaluated in the autistic patients (using only one affected individual per family,  $n=38$ ) and in 50 ethnically matched controls, after confirming that the distribution of allele frequencies were in Hardy-Weinberg equilibrium. Only two SNPs, both within the SLC25A12 gene, showed significant differences in allele frequencies between cases and controls using both allele-  
10 ( $P<0.004$ ) and genotype-based ( $P<0.03$ ) tests.

Within the SLC25A12 gene, we identified a total of five variants in the first stage screen (including the two meeting criteria for further study, indicated above). Figure 1C presents the five variants of the SLC25A12 gene identified in 47 affected subjects linked to the chromosome 2q24-q33 region. The two polymorphism  
15 meeting criteria in the first stage, rs2056202 (I3-21A/G) and rs2292813 (I16+70A/G), are G/A variants in flanking intronic sequence located 21 bp upstream of exon 4 and 70 bp downstream of exon 16, respectively. Two variants, C->T at nucleotide 99 (rs1878583) and G->A at nucleotide 1418, were within coding regions. G1418A changes arginine 473 to glutamine, while the C99T variant  
20 is silent. G1418A is a new SNP, not reported in the NCBI dbSNPs database, located in a region conserved across mammalian species, but the amino acid glutamine is observed in mice. The final variant appears in the 3' untranslated region (UTR). We did not find SNP rs1059299, reported in the public database, which changes amino acid 600, in our sample.

25 Given the evidence for association of rs2056202 and rs2292813 in a small number of cases and controls, the entire sample was genotyped at these SNPs for analysis by the Transmission Disequilibrium Test (TDT), which makes use of family-based controls. Of the 411 families studied, 197 had at least one parent

heterozygous for at least one SNP. These families included 140 multiplex and 57 singleton families. To test for association by the TDT, transmission from heterozygous parents to one affected child was analyzed (Table 1). TDT analysis demonstrated association for rs2056202 ( $\chi^2=10.83$ ,  $df=1$ ,  $P=0.001$ ) and for  
5 rs2292813 ( $\chi^2=6.23$ ,  $df=1$ ,  $P=0.01$ ). In both cases, the G allele appeared to be the risk allele (or the A allele the protective allele) (for simplicity, Table 1 and 2 show transmission data for just the G allele for both SNPs).

Table 1. TDT with one affected per family

|                     | T        | NT | $\chi^2$ | P                  | T        | NT | $\chi^2$ | P                   | T        | NT | $\chi^2$ | P                  |
|---------------------|----------|----|----------|--------------------|----------|----|----------|---------------------|----------|----|----------|--------------------|
|                     | Combined |    |          |                    | Maternal |    |          |                     | Paternal |    |          |                    |
| <b>SNPs</b>         |          |    |          |                    |          |    |          |                     |          |    |          |                    |
| rs2056202           | 116      | 71 | 10.83    | 0.001              | 53       | 30 | 6.37     | 0.01                | 53       | 31 | 5.76     | 0.02               |
| rs2292813           | 72       | 45 | 6.23     | 0.01               | 40       | 19 | 7.47     | 0.006               | 27       | 21 | 0.75     | 0.39               |
| <b>5 Haplotypes</b> |          |    |          |                    |          |    |          |                     |          |    |          |                    |
| G*G                 | 102      | 45 | 22.10    | $3 \times 10^{-6}$ | 54       | 19 | 66.52    | $3 \times 10^{-16}$ | 48       | 26 | 11.92    | $6 \times 10^{-4}$ |
| G*A                 | 8        | 9  | 0.06     | 0.81               | 3        | 8  | 2.9      | 0.09                | 5        | 1  | 3        | 0.08               |
| A*G                 | 21       | 47 | 9.94     | 0.002              | 11       | 23 | 7.11     | 0.008               | 10       | 24 | 9.84     | 0.002              |
| A*A                 | 26       | 56 | 10.98    | 0.001              | 12       | 30 | 13.76    | 0.0002              | 14       | 26 | 6.05     | 0.014              |

10 For each SNP or haplotype, the number of transmitted (T) or non-transmitted (NT) events are shown. For the individual SNPs, data is the for G allele.



TDT analysis was also carried out using multiple affected individuals per family (Table 2). Such analysis is more properly a measure of linkage rather than association. Transmission disequilibrium was observed for both rs2056202 ( $\chi^2=8.89$ , df=1, P=0.003) and rs2292813 ( $\chi^2=7.28$ , df=1, P=0.007).

5 Table 2. TDT with all affecteds per family

|           | T   | NT  | $\chi^2$ | P                  |
|-----------|-----|-----|----------|--------------------|
| SNPs      |     |     |          |                    |
| rs2056202 | 191 | 137 | 8.89     | 0.003              |
| rs2292813 | 124 | 85  | 7.28     | 0.007              |
| Haplotype |     |     |          |                    |
| 10. G*G   | 163 | 91  | 20.41    | 6X10 <sup>-6</sup> |
| G*A       | 11  | 16  | 0.93     | 0.34               |
| A*G       | 44  | 71  | 6.34     | 0.011              |
| A*A       | 55  | 95  | 10.67    | 0.001              |

15 For each SNP or haplotype, the number of transmitted (T) or non-transmitted (NT) events are shown. For the individual SNPs, data is for the G allele.

Looking at haplotypes, there was an increased transmission of the G\*G haplotype in autism when analyzing either one affected per family ( $\chi^2=22.10$ , df=1, P=0.000003) or all affecteds ( $\chi^2=20.41$ , df=1, P=0.0000006). Using a global analysis, two-locus TDT showed disequilibrium of transmission of the four  
20 observed haplotypes for both one affected per family ( $\chi^2=32.31$ , df=3, P=5X10<sup>-7</sup>) or all affecteds ( $\chi^2=28.76$ , df=3, P=0.000003).

Two-point linkage analysis using nonparametric LOD score analysis (NPL), indicated some evidence for linkage between autism and rs2056202 (NPL=1.26,

P=0.07) or rs2292813 (NPL=1.1, P=0.09) (Table 3). Two-point heterogeneity LOD (HLOD) supported this linkage, with maximal HLOD scores of 2.11 (P=0.03) and 1.15 (P=0.1), for rs2056202 and rs2292813, respectively. However, information was low at these SNPs (estimated as 0.23 and 0.34 for rs2056202 and  
5 rs2292813, respectively). To increase information we used multipoint linkage analyses with these two SNPs. Under these conditions, maximal multipoint NPL scores of 1.57 and maximal multipoint HLOD scores of 2.11 were observed (information was increased to about 0.51). The two markers showed linkage disequilibrium with each other as determined by analyzing linkage disequilibrium  
10 in unrelated patients ( $D'=0.79$ ,  $SD=0.06$ ).

Table 3. Linkage analysis of SNPs in SLC25A12

| <b>Two-point linkage analysis</b>  |  |                                    |
|------------------------------------|--|------------------------------------|
|                                    | rs2056202                                  | rs2292813                          |
| NPL                                | Z score= 1.26; P=0.07                      | Z score= 1.11; P=0.09              |
| HLOD, recessive model              | HLOD= 1.52; P=0.06; $\alpha$ =0.21         | HLOD= 1.79; P=0.04; $\alpha$ =0.28 |
| HLOD, dominant model               | HLOD= 0.75; P=0.19; $\alpha$ =0.29         | HLOD= 0.8; P=0.18; $\alpha$ =0.39  |
| <b>Multipoint linkage analysis</b> |  |                                    |
| NPL                                | Maximal Z score= 1.57; P=0.03              |                                    |
| HLOD, recessive model              | Maximal HLOD= 2.11; P=0.03; $\alpha$ =0.23 |                                    |
| HLOD, dominant model               | Maximal HLOD= 1.15; P=0.1; $\alpha$ =0.34  |                                    |

10 P values for HLOD scores were computed as described in Nyholt 2000 (36).  $\alpha$  is an estimate of the fraction of families showing linkage at the locus under study.

A genotype relative risk was also estimated for individuals carrying one or two copies of the risk alleles (the G alleles in both cases) for either rs2056202 or rs2292813. Results are given in FIG. 2. Those results show that the relative risk increases with increasing G alleles at either polymorphic site. It should also be noted that genotype relative risk estimates in TDT studies such as this underestimate the true genotype relative risk. See Risch, Theoret. Pop. Biol. 60, 215-220 (2001). Therefore, the true autism risk for the genotypes indicated in FIG. 2 is likely to be considerably higher than indicated.

### Discussion

The objective of the present work was to identify a susceptibility gene for autism in chromosome region 2q24-q33. We identified two SNPs, rs2056202 and rs2292813, in SLC25A12 that demonstrated association with autism using the TDT. Preferential transmission of the G allele for both SNPs was found in 197 informative families. Furthermore, linkage was found between autism and the SNPs by TDT and by non-parametric and parametric analyses.

The SLC25A12 gene contains 18 exons spreading over about 110 kilobases (kb) and is expressed primarily as 2.9 and 3.2kb mRNA species, predominantly in skeletal muscle, heart and brain (25). SLC25A12 cDNA has an open reading frame of 2037 bp encoding a 678 amino acids protein that is a calcium-dependent mitochondrial aspartate/glutamate carrier (AGC1). The subcellular localization of protein is exclusively mitochondrial. The amino-terminal half of AGC1 contains five putative EF hands that are able to bind  $\text{Ca}^{2+}$ , while the carboxy-terminal half harbors the aspartate/glutamate exchanger function. AGC1 is critically involved in the activity of the malate/aspartate NADH shuttle, catalyzing the electrogenic exchange of aspartate for glutamate and a proton, as well as in the urea cycle (26). Recently, it has been shown that the SLC25A12 gene, as well as AGC1, is the only form of the mitochondrial aspartate/glutamate carrier expressed in neurons and

neural stem cells (27). Protein levels increased during neuronal differentiation and are correlated with an increase in the malate/aspartate NADH shuttle activity.

SLC25A12 mRNA and the AGC1 protein are widely expressed in adult mouse CNS, particularly in neural nuclei in the brainstem (27). It has been  
5 suggested that the enrichments of AGC1 in specific neurons could reflect a tonic activity of these neurons. Dysfunction of this protein, or altered expression of this protein, may lead to an alteration in mitochondrial function and ATP synthesis. As neurons are major energy users, even modest changes in mitochondrial function and ATP synthesis may lead to selective changes in neurons. Support for a role for  
10 mitochondrial dysfunction in autism comes from a recent study demonstrating mitochondrial hyperproliferation and partial respiratory chain block in two patients with autism and a 15q inverted duplication (28).

As noted above, a region of chromosome 7 has also been shown to be linked to autism in multiple studies (29). It is interesting that a paralog of SLC25A12,  
15 namely SLC25A13 (CITRIN1 or AGC2), localizes to this region of chromosome 7. These two genes share about 79% identity, both encoding forms of aspartate/glutamate carriers, with 71% identity in the EF-hand domains and 84% within the exchanger domain. Mutations in SLC25A13 gene confers adult-onset type II citrullinemia (CTLN2, MIM#603471), an autosomal recessive disease  
20 caused by a deficiency of argino-succinate synthetase with clinical features included enuresis diarrhea, tremors, lethargy, mental retardation and psychiatric disorders. Although confirmation of the association between autism and SLC25A12 is required, it is tempting to speculate that SLC25A13 could be a candidate autism susceptibility gene on chromosome 7.

25 For both SNPs, the allele associated with autism corresponds to a common allele. One must consider that in complex disorders with multiple interacting genes, the prevalence of the susceptibility alleles may be quite high. Recent examples of this include the e4 allele of apolipoprotein E in Alzheimer's disease, NOD-2 gene

changes in Crohn's disease, and calpain-10 gene changes and type 2 diabetes mellitus (30-32). In the case of autism, with the strongest evidence for numerous interacting genes, the expectation would be that the susceptibility variants for at least some loci will be quite common, and might even contribute to behavioral variability in healthy individuals. However, in any such study the true susceptibility locus or functional polymorphisms may not have been identified but rather are in linkage disequilibrium with the variants studied. The true susceptibility locus may even be in neighboring genes. In our studies, we have examined both flanking genes. For HAT1, we did not find any useful polymorphisms. For DNCI2, we found 8 polymorphisms that were negative for association in first stage analyses.

In our studies, we identified intronic polymorphisms associated with disease. The functional relevance of such variants remains obscure in most studies. However, it is increasingly being realized that the expression of a significant number of genes is regulated by cis-acting elements and that inherited variation in gene expression may contribute to disease (33, 34). Regulation of gene expression would affect cellular function, without requiring a modification in the coding sequence, if levels of the gene product were limiting. It has recently been demonstrated that over-expression of AGC1 can lead to increased mitochondrial ATP production (35), so genetic variations that change the expression of AGC1 would be predicted to impact on ATP production. Whether the polymorphisms we identified (or additional polymorphism in linkage disequilibrium with the polymorphism we identified) affect gene expression needs to be determined.

With all association studies, especially in complex disorders thought to be due to multiple interacting genes of weak effect, we must await replication in independent samples before the results can be accepted. However, given the evidence from our study, it may be unrealistic to expect that the finding will be easily replicated by TDT in a typical sample of under 200 trios. The TDT allows for robust statistical analysis without bias of population admixture. However, it lacks

power, especially at loci such as ours, where many of the parents were homozygous at the two loci. A carefully designed case-control study, with controls matched for ethnicity, gender, and age, may have more power to detect association at these two loci. Alternatively, genotyping several hundred trios for TDT would be in order for  
5 a replication study.

Assuming that our results reflect true association of SLC25A12 with autism, the data indicate a genotype relative risk for the two-loci of between 2 and 5 (FIG. 2). This, while significant, must be taken in context of the observation that the susceptibility variants (or the variants in linkage disequilibrium with the true  
10 susceptibility variants) are common alleles. This is consistent with the idea that this locus plays a significant role in the epidemiology of the disorder but would not be immediately useful for genetic counseling, until it can be considered together with additional loci.

To further investigate SLC25A12 locus as a susceptibility gene for autism we  
15 are currently searching for additional genetic markers across the 110 kb region containing this gene, using both extant databases and sequencing in the patients we are studying, particularly of conserved non-coding regions. To date, more than 90 SNPs encompassing the SLC25A12 gene have been identified in the public databases, with at least 20 SNPs harboring a heterozygosity rate over 0.1. None of  
20 these appear in conserved non-coding regions. We are also carrying out expression studies of AGC1.

In view of the above, it will be seen that the several advantages of the invention are achieved and other advantages attained.

As various changes could be made in the above methods and compositions  
25 without departing from the scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.

All references cited in this specification are hereby incorporated by reference. The discussion of the references herein is intended merely to summarize the assertions made by the authors and no admission is made that any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and  
5 pertinence of the cited references.



Appendix - SEQ ID Nos

SEQ ID NO:1 region around rs2056262 that is amplified with SEQ ID NO:5 and  
SEQ ID NO:6 - with A form; the A at the polymorphic site is underlined

GTTACCCTGAGCTACAGTTTATATAGTAAAGGCAGATTAAATGCCTGATGCTTTCCC  
5 TTTCTTCACCAGCCAATGACGTTTTATATTTTATTCCAGGTTGATCTCCTATCAAGAG  
TTTTTGGCATTGGAATCTGTTTTATGTGCTCCAGATTCCATGTTTCATAGTGGCTTTCC  
AGTTGTTTGACAAGAGTGGAAATGGAGAGGTGACATTTGGTAAGGGAAAAAGAAGA  
TTATAAGTGATAAGTTAATGATGCTGGTCCAGTCTTCAATTGCTGAATCTAGTAACT  
AATATAGATTACTGCTTATTTGGGATCTGA

10 SEQ ID NO:2 region around rs2056262 that is amplified with SEQ ID NO:5 and  
SEQ ID NO:6 - with G form; the G at the polymorphic site is underlined

GTTACCCTGAGCTACAGTTTATATAGTAAAGGCAGATTAAATGCCTGATGCTTTCCC  
TTTCTTCACCAGCCAATGGCGTTTTATATTTTATTCCAGGTTGATCTCCTATCAAGAG  
TTTTTGGCATTGGAATCTGTTTTATGTGCTCCAGATTCCATGTTTCATAGTGGCTTTCC  
15 AGTTGTTTGACAAGAGTGGAAATGGAGAGGTGACATTTGGTAAGGGAAAAAGAAGA  
TTATAAGTGATAAGTTAATGATGCTGGTCCAGTCTTCAATTGCTGAATCTAGTAACT  
AATATAGATTACTGCTTATTTGGGATCTGA

SEQ ID NO:3 region around rs2292813 that is amplified with SEQ ID NO:7 and  
SEQ ID NO:8 - with A form; the A at the polymorphic site is underlined

20 CCGCTCAAGTGGTTGAAGTTGCAGGCTCTATAGTAGATGTTAGCAGTATTCCTATCT  
TTTATAAGGTACTCTAGATAAATTAAATGTGGTTTTCTCCTGAAAGGTGTCCCAGCT  
GCATCTCTGGTGACCCCTGCTGATGTCATCAAGACAAGACTGCAGGTGGCTGCCCCG  
CGCTGGCCAGACGACATACAGTGGTGTGTCGACTGTTTCAGGAAGATTCTCCGGG  
AAGAAGGGCCCTCAGCATTTTGGAAAGGGACTGCAGGTAGGCAGGGGCTGGAGCCA  
25 TACAGAATGGCTGGCTGGCTCTAGCGTCCTCCCCTGTGACTCAGTGGCTATCTTTAC

CACATTTGTCCTGGTTTCAAGTCTCCCCTGCCCCTGCTTCTCTTTTTTCAGCTCGAGTG  
TTTCGATCCTCTCCCCAGTTTGGTGTTACCTTGGTCACTTATGAACTTCTCCAGCGG  
TGGTTTTACATTGATTTTGGAGGCCTGTAAGTCAGCTGCTCAACTCCTTTACAAAGA  
AATCACTAAGTCCAAAACAAATGTTTGTCTGTCTACAAAAGCATTGTTGCAACTCTT  
5 AGAAAACTGATAAGACAGAACCTTTAAGACCAATGC

SEQ ID NO:4 region around rs2292813 that is amplified with SEQ ID NO:7 and  
SEQ ID NO:8 - with G form; the G at the polymorphic site is underlined

CCGCTCAAGTGGTTGAAGTTGCAGGCTCTATAGTAGATGTTAGCAGTATTCCTATCT  
TTTATAAGGTACTCTAGATAAATTAAATGTGGTTTTCTCCTGAAAGGTGTCCCAGCT  
10 GCATCTCTGGTGACCCCTGCTGATGTCATCAAGACAAGACTGCAGGTGGCTGCCCCG  
CGCTGGCCAGACGACATACAGTGGTGTTCATCGACTGTTTCAGGAAGATTCTCCGGG  
AAGAAGGGCCCTCAGCATTTTGGAAAGGGACTGCAGGTAGGCAGGGGCTGGAGCCA  
TACAGAATGGCTGGCTGGCTCTAGCGTCCTCCCCTGTGACTCAGTGGCTGTCCTTTAC  
CACATTTGTCCTGGTTTCAAGTCTCCCCTGCCCCTGCTTCTCTTTTTTCAGCTCGAGTG  
15 TTTCGATCCTCTCCCCAGTTTGGTGTTACCTTGGTCACTTATGAACTTCTCCAGCGG  
TGGTTTTACATTGATTTTGGAGGCCTGTAAGTCAGCTGCTCAACTCCTTTACAAAGA  
AATCACTAAGTCCAAAACAAATGTTTGTCTGTCTACAAAAGCATTGTTGCAACTCTT  
AGAAAACTGATAAGACAGAACCTTTAAGACCAATGC

SEQ ID NO:5 forward primer for amplifying rs2056202

20 GTTACCCTGAGCTACAGTT

SEQ ID NO:6 reverse primer for amplifying rs2056202

TCAGATCCCAAATAAGCAG

SEQ ID NO:7 forward primer for amplifying rs2292813

CCGCTCAAGTGGTTGAAGTT

SEQ ID NO:8 reverse primer for amplifying rs2292813

GCATTGGTCTTAAAGGTTCTGTCT

What is claimed is:

1. A method of evaluating an individual for relative genetic risk for autism, the method comprising determining the individual's genotype at polymorphism sites rs2056202 and/or rs2292813 of the SLC25A12 gene, wherein the presence of  
5 a G at either of the two sites indicates an increased risk for autism, and the presence of an increasing number of G's at the sites indicates an increasing risk for autism.
2. The method of claim 1, wherein the genotype are determined by one or more methods selected from the group consisting of single strand conformation  
10 polymorphism, denaturing high-performance liquid chromatography, DNA Invader, and polymerase chain reaction amplification followed by sequencing.
3. The method of claim 1, using polymerase chain reaction amplification with at least one primer comprising a sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8.
- 15 4. A set of two primers suitable for use in polymerase chain reaction, one primer comprising the sequence of SEQ ID NO:5 and the other primer comprising the sequence of SEQ ID NO:6.
5. A set of two primers suitable for use in polymerase chain reaction, one primer comprising the sequence of SEQ ID NO:7 and the other primer comprising  
20 the sequence of SEQ ID NO:8.
6. A kit comprising at least one set of primers suitable for use in polymerase chain reaction (PCR), wherein the set of primers amplifies polymorphism site rs2056202 of the SLC25A12 gene.

7. A kit comprising at least one set of primers suitable for use in polymerase chain reaction (PCR), wherein the set of primers amplifies polymorphism site rs2292813 of the SLC25A12 gene.

8. A kit comprising at least two sets of primers suitable for use in  
5 polymerase chain reaction (PCR), wherein one set of primers amplifies polymorphism site rs2056202 of the SLC25A12 gene and the second set of primers amplifies polymorphism site rs2292813 of the SLC25A12 gene.

9. The kit of claim 8, wherein one set of primers consists of a primer comprising the sequence of SEQ ID NO:5 and a primer comprising the sequence of  
10 SEQ ID NO:6, and the second set of primers consists of a primer comprising the sequence of SEQ ID NO:7 and a primer comprising the sequence of SEQ ID NO:8.

10. The kit of any one of claims 6-9, further comprising instructions for using the two sets of primers to evaluate an individual for relative genetic risk for autism by determining the genotype of the polymorphic sites rs2056202 and/or  
15 rs2292813 of the SLC25A12 gene.

9. A polynucleotide consisting of the sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4.

10. A method of identifying a form of a genetic polymorphism that is linked to autism, the method comprising identifying a polymorphism in the SLC25A12  
20 gene and determining whether one form of the polymorphism is present in autistic individuals more than another form, wherein the form that is present more often in autism is linked to autism.

11. Use of a genetic polymorphism linked to autism identified by the method of claim 10 for evaluating an individual for relative genetic risk for autism.

12. A eukaryotic cell comprising a transgenic human SLC25A12 gene.

13. The eukaryotic cell of claim 12, wherein the transgenic SLC25A12 gene  
5 comprises the sequence of SEQ ID NO:2 and/or SEQ ID NO:4.

14. The eukaryotic cell of claim 12, wherein the cell is a yeast cell.

15. The eukaryotic cell of claim 12, wherein the cell is a mammalian cell.

16. The eukaryotic cell of claim 12, wherein the cell is a brain cell.

17. The mammalian cell of claim 15, wherein the cell is in a living mammal.

10 18. A non-human animal comprising the eukaryotic cell of claim 12.


19. The non-human animal of claim 18, wherein the animal is a mammal.

20. A method of evaluating whether a compound affects autism, the method comprising contacting the compound with the eukaryotic cell of claim 12 and determining whether the compound affects expression or activity of a product of  
15 the SLC25A12 gene, wherein a compound that affects expression or activity of the product of the SLC25A12 gene affects autism.

**Abstract**

Methods and compositions are provided for evaluating an individual for relative genetic risk for autism, for identifying a form of a genetic polymorphism that is linked to autism, and for evaluating whether a compound affects autism.

# FIGURE 1





**FIGURE 2**

**AGC1, genotype relative risk**

|                   | <b>One affected<br/>per family</b> | <b>All affecteds<br/>per family</b> |
|-------------------|------------------------------------|-------------------------------------|
| <b>rs205 het</b>  | <b>1.56</b>                        | <b>1.92</b>                         |
| <b>homozygous</b> | <b>2.51</b>                        | <b>2.36</b>                         |
| <b>rs229 het</b>  | <b>3.00</b>                        | <b>2.00</b>                         |
| <b>homozygous</b> | <b>4.81</b>                        | <b>2.88</b>                         |

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/040444

International filing date: 03 December 2004 (03.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/527,630  
Filing date: 05 December 2003 (05.12.2003)

Date of receipt at the International Bureau: 31 March 2005 (31.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse